LACTOLOGY FOUNDATION

A10AC02 – Insulin (Beef), Intermediate-Acting: Toxicological and Lactological Monograph

1. ATC Classification and Pharmacological Profile

ATC code A10AC02 designates insulin (beef), intermediate-acting, within the Anatomical Therapeutic Chemical (ATC) classification group A10AC, comprising insulins and analogues for injection with an intermediate duration of action. Bovine insulin is an animal-derived peptide hormone historically used in the treatment of diabetes mellitus, particularly before the widespread introduction of recombinant human insulin and modern insulin analogues. The classification distinguishes bovine insulin from human and porcine insulin preparations according to biological origin and pharmacokinetic characteristics.

ATC/DDD Index

Bovine insulin differs from human insulin by three amino acid residues but retains the ability to activate human insulin receptors and exert the principal metabolic effects of endogenous insulin. Its pharmacological activity involves stimulation of peripheral glucose uptake, inhibition of hepatic glucose production, suppression of lipolysis and proteolysis, enhancement of glycogen synthesis, and promotion of intracellular potassium transport.

Intermediate-acting bovine insulin preparations achieve prolonged glucose-lowering activity through pharmaceutical modifications that delay absorption following subcutaneous administration. Historically, these formulations have included protamine-containing suspensions and zinc-associated insulin preparations. Their pharmacokinetic behavior is characterized by delayed onset, a discernible peak of activity, and a longer duration of action than soluble short-acting insulin.

The precise absorption profile depends on formulation characteristics, administered dose, injection site, local tissue perfusion, and individual metabolic conditions. Consequently, substantial variability in glucose-lowering activity may occur between patients and between successive administrations.

Following systemic absorption, bovine insulin undergoes receptor-mediated uptake and enzymatic degradation, predominantly involving hepatic, renal, and peripheral tissue pathways. Like endogenous insulin, it is not metabolized through the cytochrome P450 enzyme system.

An important distinguishing characteristic of bovine insulin is its greater potential for immunogenicity compared with recombinant human insulin. Structural differences between bovine and human insulin may stimulate the formation of anti-insulin antibodies, occasionally influencing insulin requirements, pharmacodynamic predictability, or hypersensitivity reactions.

Although bovine insulin has largely been superseded by recombinant human insulin and insulin analogues in many healthcare systems, its historical clinical use and continued inclusion in the ATC classification justify an independent toxicological and lactological assessment.

2. Toxicological Profile

The principal toxicological effects of intermediate-acting bovine insulin arise from excessive insulin receptor stimulation and the resulting disturbances in glucose and electrolyte homeostasis. Hypoglycemia represents the most important acute toxicological risk and may occur following excessive administration, insufficient carbohydrate intake, increased physical activity, impaired renal or hepatic function, or changes in insulin sensitivity.

Clinical manifestations range from autonomic symptoms, including sweating, tremor, palpitations, hunger, and anxiety, to neuroglycopenic manifestations such as confusion, impaired coordination, behavioral disturbances, seizures, loss of consciousness, and coma. Severe or prolonged hypoglycemia may result in permanent neurological injury and, exceptionally, death.

The intermediate duration of action is particularly relevant in overdose. Continued absorption from the subcutaneous depot may produce prolonged or recurrent hypoglycemia, requiring sustained glucose monitoring and repeated or continuous carbohydrate replacement according to clinical severity.

Insulin-mediated intracellular potassium redistribution may produce hypokalemia, particularly following substantial overdose. Severe potassium depletion from the extracellular compartment can contribute to neuromuscular dysfunction and cardiac arrhythmias.

The immunogenic potential of bovine insulin constitutes an additional toxicological consideration. Antibodies directed against bovine insulin may alter its pharmacokinetic and pharmacodynamic behavior, occasionally contributing to insulin resistance, variable glycemic responses, or delayed hypoglycemic episodes. Historical experience with animal-derived insulin preparations also documents local and systemic hypersensitivity reactions, although their frequency depends on preparation purity, formulation, and individual susceptibility.

Other recognized adverse effects include injection-site erythema, swelling, pruritus, lipohypertrophy, lipoatrophy, weight gain, and insulin-associated edema. Repeated administration into areas of lipodystrophy may further increase variability in insulin absorption.

There is no established evidence that therapeutic bovine insulin produces clinically significant direct genotoxicity or intrinsic organ toxicity. Nevertheless, its immunogenicity and pharmacodynamic variability require consideration when evaluating its overall safety compared with contemporary insulin preparations.

During the postpartum period, the rapid reduction in pregnancy-associated insulin resistance may substantially decrease maternal insulin requirements. Continued administration of previously appropriate pregnancy doses can therefore increase the risk of maternal hypoglycemia. This concern applies to bovine insulin as a consequence of its glucose-lowering activity and is particularly important during the establishment of breastfeeding.

3. Lactation Pharmacology and Breast-Milk Exposure

The lactation pharmacology of bovine insulin must be evaluated by distinguishing its potential transfer into human milk from the systemic biological availability of insulin ingested by the breastfed infant.

Insulin is a naturally occurring component of human breast milk. Maternal administration of exogenous insulin may contribute to measurable milk insulin concentrations, and studies involving insulin therapy have demonstrated the presence of exogenous insulin in breast milk. However, specific quantitative pharmacokinetic data for intermediate-acting bovine insulin during lactation are extremely limited. Consequently, its milk-to-plasma ratio, absolute milk concentration following therapeutic subcutaneous administration, and relative infant dose have not been reliably established.

NCBI Bookshelf

+1

Bovine insulin is a peptide composed of two polypeptide chains connected by disulfide bonds. Its molecular structure makes it susceptible to gastrointestinal proteolysis following oral ingestion. Although some intact dietary peptides may interact with the intestinal mucosa, systemic absorption of biologically active insulin following ordinary oral exposure is expected to be negligible.

Therefore, even if bovine insulin enters breast milk, clinically meaningful systemic insulin exposure in the breastfed infant is highly unlikely.

The presence of insulin in human milk is physiologically relevant because milk contains multiple bioactive hormones and growth-regulatory peptides. Insulin has been investigated for potential local effects on intestinal maturation and gastrointestinal development. However, observations concerning endogenous human milk insulin should not automatically be extrapolated to bovine insulin, particularly regarding immunological interactions arising from structural differences between the two molecules.

From a toxicological perspective, the theoretical possibility of gastrointestinal exposure to bovine insulin-derived peptides or epitopes deserves recognition. Nevertheless, there is insufficient clinical evidence to establish that exposure through breast milk following maternal bovine insulin treatment produces sensitization, allergic disease, or other immunologically mediated adverse effects in the infant.

Conventional relative infant dose calculations are of limited value in this setting because they do not adequately account for extensive gastrointestinal degradation and negligible systemic oral bioavailability. Moreover, reliable bovine insulin-specific milk concentration data are unavailable.

Accordingly, the lactational exposure assessment is based primarily on the peptide nature of bovine insulin, established principles of insulin pharmacology, and broader clinical experience with maternal insulin treatment rather than on direct bovine insulin-specific lactation studies.

4. Effects in the Breastfed Infant and on Lactation

Available clinical evidence does not establish a characteristic pattern of adverse effects in breastfed infants attributable to maternal administration of intermediate-acting bovine insulin. However, the absence of identified adverse outcomes should be interpreted cautiously because dedicated studies involving this particular insulin preparation are scarce.

The principal theoretical pharmacodynamic concern would be infant hypoglycemia resulting from systemic absorption of insulin ingested through breast milk. Such an effect is considered highly unlikely because insulin undergoes extensive gastrointestinal degradation and has negligible oral systemic bioavailability.

Clinical evidence concerning insulin more generally supports the compatibility of maternal insulin therapy with breastfeeding. The LactMed database recognizes insulin as a normal constituent of breast milk and considers breastfeeding acceptable in mothers requiring insulin treatment. These conclusions provide important indirect support for the lactological assessment of bovine insulin, although they do not constitute direct evidence specific to A10AC02.

NCBI Bookshelf

Potential immunological effects warrant a separate distinction. Bovine insulin differs structurally from human insulin and has historically demonstrated greater immunogenicity following parenteral administration. Nevertheless, immunogenicity following injection cannot be assumed to predict the consequences of very low oral exposure through breast milk. At present, there is insufficient evidence to conclude that maternal bovine insulin treatment increases the risk of infant sensitization, autoimmune disease, or clinically significant allergic reactions through lactational exposure.

Regarding milk production, insulin plays an important physiological role in mammary gland metabolism and the establishment and maintenance of lactation. Adequate maternal metabolic regulation is therefore important for normal lactational function.

Women with diabetes may experience delayed secretory activation, particularly when glycemic control is suboptimal or additional obstetric and metabolic risk factors are present. These associations should not be interpreted as evidence that therapeutic bovine insulin directly inhibits milk production.

Conversely, effective insulin treatment may support lactation indirectly by improving maternal metabolic stability. The available evidence does not indicate that bovine insulin has a specific suppressive effect on prolactin secretion or established milk synthesis.

Breastfeeding may influence maternal glucose utilization and insulin requirements. Increased energy expenditure associated with milk production, variable feeding frequency, and postpartum changes in insulin sensitivity can contribute to altered glycemic patterns. Maternal hypoglycemia therefore represents a more clinically relevant concern than direct insulin toxicity in the breastfed infant.

5. Lactological Safety Assessment and Clinical Recommendations

Intermediate-acting bovine insulin (A10AC02) is considered pharmacologically compatible with breastfeeding, although the direct lactation-specific evidence is limited. This assessment is based on the established characteristics of insulin as a peptide hormone, its negligible expected systemic oral bioavailability, and the extensive clinical experience supporting breastfeeding during maternal insulin therapy.

The principal limitation is the scarcity of studies specifically examining bovine insulin concentrations in breast milk, infant systemic exposure, and long-term outcomes following maternal treatment. Accordingly, the favorable safety assessment should be understood as a mechanistically supported conclusion rather than a finding established through extensive direct clinical investigation.

Breastfeeding should not ordinarily be interrupted solely because maternal treatment with bovine insulin is necessary. Expressing and discarding breast milk is not routinely indicated, and adjusting breastfeeding schedules around insulin injections is unlikely to meaningfully reduce infant exposure.

In healthy term infants, routine blood glucose monitoring is not required solely on the basis of maternal bovine insulin administration. Additional monitoring should be determined by independent clinical indications, including prematurity, feeding difficulties, neonatal illness, or pre-existing disturbances of glucose homeostasis.

Clinical management should primarily focus on optimizing maternal glycemic control. Insulin requirements should be reassessed after delivery and individualized throughout breastfeeding according to glucose monitoring, nutritional intake, activity, renal function, and changes in insulin sensitivity.

Because intermediate-acting bovine insulin may exhibit formulation-dependent absorption variability and greater immunogenicity than recombinant human insulin, clinicians should also consider the potential for unpredictable glycemic responses and anti-insulin antibody formation.

Where clinically appropriate and readily available, recombinant human insulin or a well-characterized modern insulin analogue may be preferred because of contemporary clinical experience, standardized manufacturing, and generally lower immunogenic potential. This preference does not imply that bovine insulin is intrinsically unsafe during breastfeeding.

Patients who remain metabolically stable on bovine insulin should not be required to discontinue breastfeeding or undergo an unnecessary treatment change solely because of lactation. Any transition between insulin preparations should be supervised carefully because differences in pharmacokinetics, immunogenicity, and individual insulin sensitivity may require dose adjustment.

Maternal education should emphasize recognition and management of hypoglycemia, adequate carbohydrate intake, individualized insulin dosing, and access to rapid-acting glucose sources.

The overall benefit-risk assessment strongly favors continuation of necessary insulin therapy. Inadequately controlled maternal diabetes poses established metabolic risks, whereas clinically significant systemic exposure of the breastfed infant to bovine insulin through breast milk is not expected.

Thus, the principal safety considerations involve maternal glycemic stability and the comparatively limited contemporary evidence base for bovine insulin, rather than an established lactational toxicological hazard.

6. Conclusion

Intermediate-acting bovine insulin, classified under ATC A10AC02, is an animal-derived insulin preparation with established glucose-lowering activity mediated through the human insulin receptor. Its toxicological profile is dominated by pharmacodynamic effects, particularly hypoglycemia and hypokalemia, while its greater immunogenic potential represents an additional consideration compared with recombinant human insulin.

From a lactological perspective, bovine insulin is expected to present a very low risk of clinically significant systemic exposure in the breastfed infant. Its peptide structure, susceptibility to gastrointestinal degradation, and negligible expected oral bioavailability provide a strong mechanistic basis for compatibility with breastfeeding.

Nevertheless, direct evidence concerning bovine insulin transfer into human milk, infant systemic exposure, and long-term developmental or immunological outcomes remains limited. The favorable assessment therefore relies predominantly on established pharmacological principles and broader clinical experience with insulin therapy.

There is no established indication for routine breastfeeding interruption, milk expression and disposal, or infant laboratory surveillance solely because of maternal treatment with intermediate-acting bovine insulin.

The principal clinical priority remains maintenance of maternal metabolic stability, particularly during the postpartum period when insulin requirements may change rapidly. Careful dose individualization, prevention of maternal hypoglycemia, and consideration of immunogenicity are important components of safe treatment.

In conclusion, bovine intermediate-acting insulin (A10AC02) is considered compatible with breastfeeding, with a very low anticipated lactational toxicological risk but limited substance-specific clinical evidence. Necessary insulin therapy should be maintained, while contemporary human insulin preparations may be preferred when clinically appropriate because of their more extensive modern clinical experience and lower immunogenic potential.